Pharming Group N.V.
PHAR · XNASCIK 1828316fmd_0PJFRSWD73ZR9BZZ3TY99TPNN5Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2018 to Dec 31, 2025, 8 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Total revenues | 189 | 212 | 199 | 206 | 245 | 297 | 376 |
| Cost of revenue | 24 | 24 | 21 | 18 | 25 | 35 | 46 |
| Gross profit | 165 | 189 | 178 | 188 | 220 | 262 | 331 |
| Research and development | 32 | 39 | 70 | 53 | 69 | 83 | 100 |
| Total operating expenses | 98 | 114 | 167 | 184 | 249 | 273 | 311 |
| Operating income | 68 | 76 | 14 | 18 | (5) | (9) | 26 |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income before taxes | 52 | 44 | 23 | 15 | (12) | (8) | 13 |
| Income tax expense | 12 | 6 | 7 | 1 | (1) | 3 | 10 |
| Net income from continuing operations | 41 | 38 | 16 | 14 | (11) | (12) | 3 |
| Net income | 41 | 38 | 16 | 14 | (11) | (12) | 3 |